Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Clemons Miller, Annette R ^a,b   Chatta, Gurkamal S ^a,b   Hutchins, Laura ^b   Angtuaco, Edgardo J ^b   Ravaggi, Antonella ^b,c   Santin, Alessandro D ^b,c   Cannon, Martin J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDIUM; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MART1 ANTIGEN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; MONOPHENOL MONOOXYGENASE; PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CASE REPORT; CD8+ T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; MELANOMA; MENINGIOMA; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TISSUE DISTRIBUTION;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INDIUM; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; MELANOMA; MEMBRANE GLYCOPROTEINS; MENINGEAL NEOPLASMS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035286982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., and Rosenberg, S. A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst., 83: 932-937, 1991.
2. Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., Carasquillo, J. A., Steinberg, S. M., Rosenberg, S. A., and Yang, J. C. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer (Phila.), 73: 1731-1737, 1994.
3. Ravaud, A., Legrand, E., Delaunay, M. M., Bussières, E., Coulon, V., Cany. L., Huet, S., Verdier, D., Kind, M., and Chomy, F. A Phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br. J. Cancer, 71: 331-336, 1995.
4. Keiholz, U., Scheibenbogen, C., Brado, M., Georgi, P., Maclachlan, D., Brado, B., and Hunstein, W. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur. J. Cancer, 30A: 103-105, 1994.
5. Dutcher, J. P., Creekmore, S., Weiss, G. R., Margolin. K., Markowitz, A. B., Roper, M., Parkinson, D., Ciobanu, N., Fisher, R. I., and Boldt, D. H. A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J. Clin. Oncol., 7; 477-485, 1989.
6. Kradin, R. L., Kurnick, J. T., Lazarus, D. S., Preffer, F. I., Dubinett, S. M., Pinto, C. E., Gifford, J., Davidson, E., Grove, B., and Callahan, R. J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet, 1: 577-580, 1989.
7. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
8. Brichard, V., Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
9. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
10. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
11. Gaugler, B., Van cen Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen. E., Lethé, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
12. Kirkin, A. F., Dzhandzhugazyan, K., and Zeuthen, J. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp. Clin. Immunogenet., 15: 19-32, 1998.
13. Oelke, M., Moehrle, U., Chen, J., Behringer, D., Cerundolo, V., Lindemann, A., and Mackensen, A. Generation and purification of CD8+ Melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumoi immunotherapy. Clin. Cancer Res., 6: 1997-2005, 2000.
14. Abdel-Wahab, Z., DeMatos, P., Hester, D., Dong, X. D., and Seigler, H. F. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Cell Immunol., 186: 63-74, 1998.
15. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
16. Rivoltini, L., Squarcina, P., Loftus, D. J., Castelli, C., Tarsini, P., Mazzocchi, A., Rini, F., Viggiano, V., Belli, F., and Parmiani, G. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res., 59: 301-306, 1999.
17. Valmori, D., Pittet, M. J., Rimoldi, D., Liénard, D., Dunbar, R., Cerundolo, V., Lejeune. F., Cerottini, J. C., and Romero, P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res., 59: 2167-2173, 1999.
18. Kaplan, J. M., Yu, Q., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., and Roberts, B. L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol., 163: 699-707, 1999.
19. Kirkin, A. F., Thor, S., Hansen, M. R., Barfoed, A., Dzhandzhugazyan, K. N., and Zeuthen, J. Establishment of gp100 and MART-1/ Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol. Immunother., 48: 239-246, 1999.
20. Beightol, R. W., and Baker, W. J. Labeling autologous leukocytes with indium-111 oxine. Am. J. Hosp. Pharm., 37: 847-850, 1980.
21. Dutcher, J. P. Labeled cells in patients with malignancy. Semin. Nucl. Med., 14: 251-261, 1984.
22. Müller, C., Zielinski, C. C., Linkesch, W., Ludwig, H., and Sinzinger, H. In vivo tracing of indium-111 oxine-labeled human peripheral blood mononuclear cells in patients with lymphatic malignancies. J. Nucl. Med., 30: 1005-1011, 1989.
23. Mackensen, A., Krause, T., Blum, U., Uhrmeister, P., Mertelsmann, R., and Lindemann, A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol. Immunother., 48: 118-122, 1999.
24. Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., and Rosenberg, S. A. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-AI, -A2, and -A3 alleles. J. Immunol., 161: 6985-6992, 1998.
25. Romero, P., Gervois, N., Schneider, J., Escobar, P., Valmori, D., Pannetier, C., Steinle, A., Wolfel, T., Lienard, D., Brichard, V., Van Pel, A., Jotereau, F., and Cerottini, J. C. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol., 159: 2366-2374, 1997.
26. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
27. Skipper, J. C., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L. J. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer. 82: 669-677, 1999.
28. de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57: 3223-3229, 1997.
29. Sarantou, T., Chi, D. D., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, D. S. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
30. Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., and Blair, G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 338: 1227-1229, 1991.
31. Hoon, D. S., Wang, Y., Dale, P. S., Conrad, A. J., Schmid, P., Garrison, D., Kuo, C., Foshag, L. J., Nizze, A. J., and Morton, D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol., 13: 2109-2116, 1995.
32. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D., and Schuler, G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods, 196: 137-151, 1996.
33. Rieser, C., Böck, G., Klocker, H., Bartsch, G., and Thurnher, M. Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J. Exp. Med., 186: 1603-1608, 1997.
34. + T-cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood, 91: 3875-3883, 1998.
35. Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., and Frelinger, J. G. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA. 94: 6369-6374, 1997.
36. Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., and Ohta, A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med., 190: 617-627, 1999.
37. Shimizu, K., Okamoto, Y., Miyao, Y., Yamada, M., Ushio, Y., Hayakawa, T., Ikeda, H., and Mogami, H. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J. Neurosurg., 66: 519-521, 1987.
38. Heimans, J. J., Wagstaff, J., Schreuder, W. O., Wolbers, J. G., Baars, J. W., Polman, C. H., Scharenberg, J. G., Scheper, R. J., Palmer, P. A., and Franks, C. R. Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surg. Neurol., 35: 244-247, 1991.
39. r 55,000 protein). Cancer Res., 52: 1123-1128, 1992.
40. Samlowski, W. E., Park, K. J., Galinsky, R. E., Ward, J. H., and Schumann, G. B. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J. Immunother., 13: 49-54, 1993.
41. Herrlinger, U., Weller, M., and Schabet, M. New aspects of immunotherapy of leptomeningeal metastasis. J. Neurooncol., 38: 233-239, 1998.
42. Savas, B., Arslan, G., Gelen, T., Karpuzoglu, G., and Ozkaynak, C. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res., 19: 4413-4420, 1999.
43. Tsurushima, H., Liu, S. Q., Tuboi, K., Matsumura, A., Yoshii, Y., Nose, T., Saijo, K., and Ohno, T. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res., 90: 536-545, 1999.
44. Moore, K. W., O'Garra, A., de Waal Malefyt, R., Vieira, P., and Mosmann, T. R. Interleukin-10. Annu. Rev. Immunol., 11: 165-190, 1993.
45. Salazar-Onfray, F., Charo, J., Petersson, M., Freland, S., Noffz, G., Qin, Z., Blankenstein, T., Ljunggren, H. G., and Kiessling, R. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol., 159: 3195-3202, 1997.
46. de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and de Vries, J. E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med., 174: 915-924, 1991.
47. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q. J., Masucci, M. G., and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180: 2371-2376, 1994.
48. + cytotoxic T lymphocytes. J. Virol., 74: 4729-4737, 2000.
49. Foon, K. A., Lutzky, J., Baral, R. N., Yannelli, J. R., Hutchins, L., Teitelbaum, A., Kashala, O. L., Das, R., Garrison, J., Reisfeld, R. A., and Bhattacharya-Chatterjee, M. Clinical and immune responses in advanced melanoma patients immunized with an antiidiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol., 18: 376-384, 2000.